Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
KORU Medical (TASE:BLWV) Systems, Inc. (NASDAQ:KRMD), a $141 million market cap company specializing in surgical and medical instruments, reported the outcomes of its annual shareholder meeting held on May 14, 2025. According to InvestingPro data, the company’s stock has experienced an 8.5% decline over the past week, though it maintains a solid financial position with a current ratio of 2.44. The meeting saw several key proposals put to vote, including the election of directors, approval of executive compensation, and ratification of the company’s independent accountants for the fiscal year 2025. While KORU operates with a moderate level of debt and maintains strong liquidity, InvestingPro analysis indicates analysts don’t expect profitability this year, with projected EPS of -$0.10.
In the election of directors, all nominees were successfully elected to the board. Shareholders cast a total of 36,949,703 votes, with a significant number of broker non-votes recorded for each nominee. The detailed voting results indicated a clear majority in favor of the appointed directors. R. John Fletcher, Robert A. Cascella, Donna French, Joseph M. Manko, Jr., Shahriar (Shar) Matin, Linda Tharby, and Edward Wholihan will thus serve on the board.
The second proposal, concerning the approval of executive compensation, received advisory approval from the shareholders. The vote count showed 23,167,952 for, 702,827 against, and 81,599 abstentions, alongside 12,997,325 broker non-votes.
Lastly, the appointment of Cherry Bekaert (EBR:BEKB) LLP as the company’s independent registered public accountants for the 2025 fiscal year was ratified. The proposal received overwhelming support, with 36,910,101 votes in favor, 9,621 against, and 29,981 abstentions.
The SEC filing, which serves as the source for this information, provides no further context on the implications of these results for KORU Medical Systems’ operations or strategy moving forward. Despite current challenges, the company has achieved 19.7% revenue growth in the last twelve months. For deeper insights into KORU’s financial health and growth prospects, investors can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports.
In other recent news, KORU Medical Systems reported a strong start to 2025 with its first-quarter revenue reaching $9.6 million, surpassing forecasts by 9.3% and marking an 18% year-over-year increase. This positive performance prompted the company to raise its full-year revenue guidance to between $38.5 million and $39.5 million. KORU Medical Systems is actively pursuing strategic expansion in international markets, with a notable 36% growth in international core revenue, driven by new distributor relationships and a key tender win in Europe. The company continues to maintain a strong position in the subcutaneous immunoglobulin (SCIG) drug delivery market, supporting approximately 45,000 chronic patients globally. Additionally, KORU Medical Systems plans to submit two new drugs for clearance with its Freedom Infusion System by the end of 2025, expanding its pipeline to five submissions. The company also reported a gross margin of 62.8%, a 50 basis point improvement from the previous year. Despite facing challenges such as net losses and competitive pressures, KORU Medical Systems remains focused on its strategic priorities and anticipates sustainable revenue growth of over 20%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.